Evidence types
Phase 3 clinical trial articles covering late-stage treatment evidence, safety, effectiveness, and regulatory context in IBD. Research context emphasizes studies, trials, biomarkers, mechanisms, and emerging IBD science.
Page 4 of 4 · 158 articles
Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full details.
Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...
Long-term maintenance of clinical and endoscopic remission is a key goal in Crohn’s disease care. Positive two-year data and FDA approval may affect treatment options for adults, including people who previously failed...
These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...
Long-term data matter because they show whether benefits and safety of a new biologic hold up beyond the initial trial period. For people with Crohn’s disease, sustained clinical remission and endoscopic healing are...
Durable treatment responses matter to people with Crohn’s disease because sustained clinical remission and endoscopic improvement can mean fewer symptoms and less inflammation over time. Longer safety and durability data...
This article reports two-year data showing that mirikizumab (Omvoh) maintained clinical and endoscopic benefit for many people with moderate–severe Crohn’s disease, and that results across Phase 3 programs also support...
This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...
Long-term results matter because they report whether an IL‑23 inhibitor (Omvoh) maintained clinical and endoscopic improvements through two years for people with moderate-to-severe Crohn’s disease, including some with...
This press release reports multi-year clinical trial data suggesting sustained remission and intestinal healing with Omvoh (mirikizumab) in patients with Crohn's disease—information that could affect treatment...
This trial suggests a new IL‑23 inhibitor, mirikizumab, may be an effective and safe treatment option for adults with moderate-to-severe Crohn's disease who have not responded to prior therapies. Positive phase 3 results...
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...
A pipeline overview can indicate which new drugs and trials might affect future treatment options for Crohn’s disease. Patients on biologics or those with treatment-refractory disease may see new options under study that...
